Astellas to sift Vietnam's biodiversity for drug leads
This article was originally published in Scrip
The soil of northern Vietnam might appear to be an unlikely place to find novel research leads, but this is precisely where Astellas will be looking as part of a new drug discovery collaboration.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.